ReviewNew emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
Under a Creative Commons license
open access
cluster of differentiation 40
CD40
TNFR5
immune modulating cancer therapy
immune checkpoint inhibitor
selicrelumab
CP-870,893
APX005M
Cited by (0)
Contributors: MP: performed literature search, developed structure and outline and wrote the manuscript. ASB: supervised literature search and corrected and wrote the manuscript.
Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests: ASB has research support from Daiichi Sankyo, Hoffmann La-Roche and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie.
Patient consent for publication: Not required.
Provenance and peer review: Not commissioned; externally peer reviewed.
© 2019 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.